西妥昔单抗联合GP方案治疗晚期非小细胞肺癌临床观察  

Clinical observation of cetuximab combined with gemcitabine and cisplatin for advanced non-small-cell lung cancer

作　　者：缪建华[1] 钟皎[2] 过雪丹[1] 吕蕾[3] 

机构地区：[1]江苏省无锡市第二人民医院肿瘤内科,江苏无锡214002 [2]江苏省无锡市第二人民医院药剂科,江苏无锡214002 [3]江苏省无锡市第二人民医院呼吸内科,江苏无锡214002

出　　处：《实用临床医药杂志》2012年第3期90-92,共3页Journal of Clinical Medicine in Practice

摘　　要：目的评价西妥昔单抗联合吉西他滨和顺铂(GP)方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应。方法将62例晚期NSCLC患者随机分为2组,治疗组采用西妥昔单抗联合GP方案化疗,对照组单纯GP方案化疗。评价近期疗效、生存情况及毒副反应。结果 2组总有效率无显著差异,治疗组无进展生存期(PFS)较对照组显著延长(P<0.01)。2组主要毒副反应为骨髓抑制、贫血、胃肠道反应及皮疹,但对照组皮疹发生率显著低于治疗组(P<0.05)。结论西妥昔单抗联合GP方案治疗晚期NSCLC的疗效较好,毒副反应可耐受,值得进一步扩大病例数进行观察。Objective To assess the efficacy and safety of cetuximab combined with gemcitabine and cisplatin（GP） for advanced non-small-cell lung cancer（NSCLC）.Methods Sixty-two patients with advanced NSCLC were divided into two groups.The treatment group received cetuximab combined with GP,and the control group only received GP.The short-term effect,survival conditions and adverse events were evaluated.Results The overall efficacy rates showed no obvious difference between the two groups.The PFS in the treatment group was obviously higher than that in the control group（P〈0.01）.The main adverse events of the two groups were myelosuppression,anemia,nausea,vomiting and efflorescence.The incidence rate of efflorescence in the control group was lower than that in the treatment group（P〈0.05）.Conclusion The effect of cetuximab combined with GP therapy on advanced NSCLC is better and the adverse events are tolerable.It’s valuable to do more research.

关 键 词：西妥昔单抗 吉西他滨 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]